Compare Bristol-Myers Squibb Co (BMY) vs Wolfspeed Inc (WOLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Wolfspeed Inc — how do they compare? Bristol-Myers Squibb Co trades at $56.95 (market cap $116.30B), while Wolfspeed Inc trades at $35.3 (market cap $1.78B). The key difference: Bristol-Myers Squibb Co is far larger — about 65.3× Wolfspeed Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Wolfspeed Inc pays none. Which is the better fit depends on your goals.
| BMY | WOLF | |
|---|---|---|
Market Cap | $116.30B | $1.78B |
Sector | Health | Technology |
52-Week High | $62.37 | $73.68 |
52-Week Low | $42.60 | $1.19 |
Enterprise Value | $152.24B | $2.44B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Wolfspeed (WOLF) trades at $33.65, down 4.65% today amid bearish technical signals and negative profitability metrics. The stock shows mixed earnings performance with recent beats but a significant Q4 2025 miss. Recent developments include a patent lawsuit against Navitas Semiconductor and strategic partnerships with GE Aerospace, positioning the company in high-growth AI and defense markets despite current financial challenges.
The outlook remains cautious with analyst consensus leaning neutral (47.37% Hold). While strategic pivots to data centers and defense offer growth potential, negative margins and bearish technicals present near-term risks. Investors should monitor earnings improvement and market share gains in silicon carbide technology for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Wolfspeed Inc
Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.
Read more on WOLF →
